Focused On-demand Library for 5'-AMP-activated protein kinase subunit beta-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y478

UPID:

AAKB1_HUMAN

Alternative names:

Alternative UPACC:

Q9Y478; Q9UBV0; Q9UE20; Q9UEX2; Q9Y6V8

Background:

The 5'-AMP-activated protein kinase subunit beta-1 is a pivotal component of the AMPK complex, a crucial energy sensor in cells. It regulates energy metabolism by activating pathways that generate ATP and inhibiting those that consume energy. This subunit serves as a scaffold for the assembly of the AMPK complex, coordinating the activity of alpha and gamma subunits to ensure efficient energy management and cellular homeostasis.

Therapeutic significance:

Understanding the role of 5'-AMP-activated protein kinase subunit beta-1 could open doors to potential therapeutic strategies. Its central role in energy metabolism and cellular growth makes it a promising target for interventions in metabolic disorders and cancer.